Brain tumor vaccine links mutation targeting to eight-year survival gains
Researchers have published long-term results from a clinical trial showing that a peptide vaccine targeting a specific IDH1 mutation can improve survival rates for patients with high-grade astrocytomas. The vaccine works by training the immune system to recognize and attack tumor cells carrying the mutation.
Why it matters
This breakthrough offers a potential new immunotherapy treatment for gliomas, which are typically incurable and difficult to treat with standard surgery or chemotherapy.
edited by Gaby Clark , reviewed by Andrew Zinin
The article is a scientific report on medical research findings without political or social bias.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in